Execution Over Protection: Looking Beyond the Licensing-First Approach

What you will learn

• Account honestly for what IP protection costs an early venture in time, disclosure, capital, rigidity, and culture
• Recognise execution moats: customer knowledge, speed, relationships, tacit expertise, and revenue
• Identify the market structures (pharma, licensed content, easy replication) where protection is the appropriate model
• Form a tentative protect-first or execute-first position for your own field, and document why you reached that conclusion

Read this before the session. The discussions will go deeper if you arrive with a position, even a tentative one.

The Core Argument

Here is the claim this lesson asks you to test:

For most research-based ventures, IP protection adds less competitive value than the time, money, and energy it costs, and a relentless focus on execution will build a more durable business faster.

That claim is not always true. The session is designed to find the edges where it breaks down.

But it is true more often than researchers expect. The default assumption in academic institutions tends to be "protect first, then commercialise." This position reflects the incentives of technology transfer offices and IP lawyers more than it reflects the realities of building a business. Those incentives are real and legitimate; they just need to be reconciled with your incentives.

What Protection Costs You

The costs of IP protection are visible on an invoice (i.e., what you paid to receive protection). The costs it imposes on your business, current and future, are less obvious and need to be thought through.

Time. A patent application takes 2–4 years to grant. During that window, you may be legally restricted from disclosing the full details of your approach to potential customers, partners, or collaborators. Every month you're protecting is a month a competitor who chose not to protect is talking to customers, iterating, and learning.

Disclosure. Patents require full public disclosure of your invention. Once filed, your approach is visible to any competitor who searches the literature, often before you've reached the market. The secrecy that provisional patents offer expires. Protection eventually means revealing.

Capital. International patent portfolios cost $15,000–$50,000+ to file, and require ongoing maintenance fees in each jurisdiction. For an early-stage venture with limited runway, that is capital being diverted away from core operations, such as product development, customer discovery, or hiring.

Rigidity. Patents protect a specific implementation. If the market tells you your approach needs to change, and it usually does, you may be protecting the wrong thing. Execution-first organisations can pivot. Patent-first organisations are often anchored to what they filed.

Culture. NDAs, secrecy protocols, and IP restrictions create friction in research environments built on openness and collaboration. They can damage relationships with the academic ecosystem that produced your innovation in the first place and create rifts with core collaborators.

What Execution Gains You

Execution-first organisations invest the same time and money in a different set of advantages:

Customer knowledge. Every week you're talking to customers instead of filing paperwork is a week of learning. Who actually needs this? What are they willing to pay? What's the workflow it fits into? This knowledge is tacit, personal, and genuinely hard for competitors to replicate.

Speed to market. First-mover advantage is a documented reality, though the advantage is often overstated. The compounding effect of getting feedback earlier can be more advantageous than planting a flag and make the venture more reliable. Organisations that ship faster have the ability to improve faster.

Relationships. The customers, collaborators, and distribution partners you build relationships with early create switching costs. These switching costs go beyond contractual obligations: once trust, history, and integration have accumulated, it's difficult to pivot. But a competitor with a better product may still lose to you because your customers don't want to retrain their staff and risk a transition.

Tacit knowledge. The deep, embodied expertise your team accumulates through doing, the failures that don't appear in any paper, and the workarounds that took six months to find are difficult to replicate. This learning doesn't appear in a patent application and often gets lost over time because it lives in people. Documenting and transmitting tacit knowledge can be a key advantage.

Revenue. Revenue funds the next iteration. A business generating $200K/year from early customers is more defensible than a business with a pending patent and no revenue.

What Protection Gains You

IP protection has clear merits that should not be ignored in pursuit of execution.

Legal standing. A patent gives you the same legal standing as a multinational corporation when defending against infringement. Without it, a well-funded competitor can replicate your approach and you have little recourse.

Licensing income. In some industries, the most economically rational path is not to build a business but to license your invention. Pharmaceutical compounds, certain semiconductor designs, and materials innovations often have more value as licences than as ventures. If this is your model, protection is the primary way forward.

Investor confidence. Many investors, particularly in life sciences and deep tech, require a defensible IP portfolio before they will write a cheque. The patent, often viewed only as evidence of business viability, is also a signal that the underlying science has been validated and disclosed. In capital-intensive industries, this signal matters.

Freedom to operate. Knowing what you own and what competitors own lets you navigate the patent landscape without accidental infringement. A freedom-to-operate analysis is valuable even if you never file a patent yourself.

Deterrence. A portfolio of patents can deter competitors from entering your space, even if you never intend to litigate. The threat of expensive litigation is often enough.

What Execution Costs You

Execution-first organisations also experience costs that protection-first organisations do not.

Copycat vulnerability. If your innovation is easy to replicate (e.g., a software feature, a process improvement, a formulation), a well-funded competitor can build it in a fraction of the time it took you, without bearing your R&D costs. In markets where replication is cheap, protection matters more.

Platform risk. For software and digital tools, large platform companies can replicate your functionality and distribute it to their installed base in a product update. Execution moats can be erased by incumbents with distribution advantages. This is a structural risk that no amount of execution can fully mitigate without some form of protection or platform lock-in.

Capital access. As noted above, some investors simply will not invest without IP. If your path requires venture capital, and your investors require patents, execution-first is a disqualifier.

Pharma is different. In pharmaceutical development, the economics of clinical trials are so extreme--often hundreds of millions of dollars and a decade of development--that no company would invest without the monopoly pricing that patent protection enables. Execution without protection in drug development is not a viable model. Think about if your industry is subject to similar economics or policies.

Four Case Studies

These cases are deliberately in tension. Read all four and come to the session prepared to argue about them.

In practice, "read all four" means deep knowledge of your chosen pair and surface familiarity with the rest. Read one pair in depth: Basecamp and Moderna form one pair; Spotify and CRISPR form the other, the same two pairs Discussion 4 assigns in the session. Each case study below folds its full write-up behind a "Read more" toggle; expand the pair you'll argue and skim the headings and opening lines of the other two.

Case Study 1: Basecamp: The Execution Purist

37signals (now Basecamp) built project management software in 2004 with essentially no IP protection.

Case Study 2: Moderna vs. Pfizer/BioNTech: When Patents Are Existential

In 2022, Moderna sued Pfizer and BioNTech for infringing patents on mRNA vaccine technology.

Case Study 3: Spotify: Execution on Someone Else's IP

Spotify built one of the most successful consumer technology companies of the past two decades without owning any of the content it delivers.

Case Study 4: The CRISPR Patent War: Science, Priority, and Billions

Jennifer Doudna at UC Berkeley and Feng Zhang at the Broad Institute independently developed key elements of CRISPR-Cas9 gene editing within months of each other.

Counter-Examples: When the Execution Argument Fails

The case for execution-first is strong, but it is not universal. Four shorter cases challenge the lesson's main argument:

Napster vs. Spotify. Napster hit 80 million users in 18 months, the fastest consumer tech adoption of its era, and was shut down in 2001 anyway: not for poor execution, but because it had no legal right to distribute the music it distributed. Spotify launched with the same value proposition but spent two years pre-launch securing licences before building a user base. What this shows: execution without a legal right to operate can become a liability instead of a moat. Where your core input is owned by someone else (music, pharmaceutical compounds, proprietary datasets), IP protection is essential.

Dyson. James Dyson filed patents on his cyclone vacuum in the early 1980s after three years of prototyping, then spent nearly two decades in licensing disputes with copycats. The patents didn't stop copying forever, but they bought the years he needed to build the brand and distribution that became the strategic moat. What this shows: execution moats take years to compound; protection can be the thing that buys you that time rather than something in competition with it.

The Lipitor patent cliff. When Pfizer's best-selling drug lost patent protection in 2011, revenue dropped roughly 70% within a year. This was not a result of poor execution; revenue dropped because generics could now produce an identical compound at a fraction of the cost. What this shows: execution moats don't survive markets where the product can be exactly replicated. The question isn't "can they copy me today?" but "can they copy me in five years, when I need the business to still be viable?"

Amazon's one-click patent. Widely mocked as trivial when filed in 1999, it blocked Barnes & Noble from a similar checkout for years and forced Apple to pay for a licence, during the exact window when checkout friction most affected purchase decisions. What this shows: even in software, a precisely targeted patent at the right moment can matter. Most software creations don't work this way, but it is worth considering whether yours is in the minority that does.

Reflection Prompts

Bring your thinking on these case studies to the session. There are no right answers.

1. Which of the four case studies most closely resembles your field? Not your specific work, but the structural economics of your research area? Why?
2. If a well-funded competitor started working on something similar to your current research today, what would they actually need to replicate you? How long would it take?
3. Is there something you're currently keeping confidential that might be more valuable if it were public? What's the argument for and against disclosure?

Before You Begin

Discussion 1: The Copycat Test (10 min)

Discussion 2: The Cost Accounting Argument (10 min)

Discussion 3: The Customer Doesn't Care (15 min)

Discussion 4: The Conflicting Cases (15 min)

Discussion 5: Your Honest Assessment (10 min)

Produce a moat argument, and make it something you can use. This feeds into mentoring check-ins and 90-day planning.

Your Moat Map

Work through this for one piece of research, technology, or expertise you're actively developing.

Part 1, The Replication Analysis

List everything a well-funded competitor would need to replicate your work:

• Scientific or technical knowledge
• Equipment or infrastructure
• Data, samples, or proprietary materials
• Relationships (clinical, industrial, regulatory)
• People and tacit expertise
• Time

For each item, estimate how long would it take them to acquire it and how much would it cost. Mark each one: easy to replicate / hard to replicate / essentially irreplicable.

Part 2, The Moat Candidates

From your list, identify the 2–3 things that are hardest to replicate. For each, decide which category it falls into:

• IP-based: protected by a patent, trade secret, or copyright
• Execution-based: the result of accumulated doing: speed, iteration, tacit knowledge
• Relationship-based: trust, access, and history that takes years to build
• Structural: first-mover network effects, switching costs, platform position

Part 3, The Honest Trade-off

Answer these directly:

1. If you spent the next $30,000 on patent filing instead of product development, customer discovery, or hiring, would your competitive position be stronger or weaker in 18 months?
2. What is the thing you're most tempted to protect that you should probably just publish or open source? What's stopping you?
3. What is the thing you're most tempted to leave unprotected that probably needs protecting? What's stopping you?

Part 4, The Moat Argument

Write one paragraph, 100–150 words, as if you're answering the question an investor just asked: "What stops a well-resourced competitor from copying you?"

Do not mention patents unless patents are genuinely your answer. If your moat is execution, say so. If it's relationships, say so. If you don't have a convincing moat yet, say that too, and explain the steps you'd take to develop the moat.

Bring this to your next mentoring check-in.

Key Concepts Reference

Execution moat: competitive advantage derived from superior speed, quality, iteration, or accumulated know-how rather than legal protection. Often more durable than IP in fast-moving markets and more fragile in capital-intensive ones.

Replication cost: how much time and money a competitor would need to reproduce your capability. High replication cost is a feasible moat regardless of patent status.

Tacit knowledge: knowledge embedded in people and practice that cannot be fully written down or transferred through documentation. The accumulated expertise of a team that has done something for years is often the hardest thing for a competitor to replicate.

Switching costs: the friction a customer faces when moving from your product to a competitor's. Can be technical (integrations, data formats), relational (trust, training, history), or contractual.

Platform risk: the vulnerability of a product that competes inside a platform controlled by a larger player. The platform owner can replicate your features at near-zero marginal cost and distribute them to their user base in a product update.

Freedom to operate (FTO): an analysis of whether you can build and sell your product without infringing existing patents. An FTO statements is useful even if you never file a patent of your own.

Licensing model: a business model in which value is captured through charging others for the right to use your IP, rather than through building and selling a product or service. Requires strong IP protection; often more appropriate in capital-intensive industries than in software or services.